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delay in gastric emptying. In hGSMC, bitter compounds evoked Ca͸+-rises and increased ERK-
phosphorylation. Healthy volunteers showed an impaired fundic relaxation in response to nutrient 
infusion and a decreased nutrient volume tolerance and increased satiation during an oral nutrient 
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hunger signalling.
Taste perception on the tongue is essential in judging the quality of ingested food1. Bitter taste, sensed 
by 25 subtypes of the taste receptor type 2 (TAS2R) family of GPCRs, is an aversive stimulus and con-
sidered to be a toxicity detector2. Receptor stimulation results in activation of the taste-specific G-protein 
gustducin, stimulating a signalling cascade leading to the release of calcium from intracellular stores 
and activation of the membrane cation channel transient receptor potential M5 (TRPM5). This causes 
cell depolarization and neurotransmitter release, activating sensory nerves that communicate with the 
brain3. Recently, taste receptors have been identified in extra-oral tissues, suggesting additional func-
tions for these receptors besides taste perception4. In the gut, taste receptors on endocrine cells sense 
nutrients to control the release of gastrointestinal hormones, which modulate ingestive behavior5. More 
specifically, TAS2Rs have been demonstrated on enteroendocrine cell lines and affect the secretion of the 
anorexigenic peptides cholecystokinin (CCK) and glucagon like peptide (GLP-1), while gavage of bitter 
tastants induced CCK-dependent hindbrain activation6–9. In addition, intra-gastric administration of a 
bitter mixture resulted in the release of the hunger hormone ghrelin, partially involving α -gustducin. 
This was associated with a short-term increase in food intake, followed by a long-term decrease in food 
intake, correlating with a decrease in gastric emptying10. These results suggest a potential role for bitter 
tastants in appetite regulation. In the central nervous system, functional bitter taste receptors were found 
in multiple regions of the rat and human brain11–13. Studies in airway smooth muscle have demonstrated 
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the relaxing potential of bitter agonists on human and mouse smooth muscle14. Furthermore, inhaled 
bitter tastants counteracted asthmatic bronchoconstriction in a mouse model suggesting that TAS2Rs 
may represent novel targets for treating asthma.
Using a translational approach, the present study aimed to investigate whether TAS2Rs are also pres-
ent on intestinal smooth muscle cells and influence gut contractility. The contractile potency of several 
bitter agonists was compared in different regions of the gut and the mechanism of action was determined. 
Additionally, the effect of intra-gastric administration of bitter tastants on gastric emptying in mice was 
further characterized. A human gastric smooth muscle cell culture was used to translate the molecular 
events induced by bitter agonists from mice to humans, while in two studies in healthy volunteers; the 
effect of bitter agonists on gastric accommodation, satiation and nutrient volume tolerance was studied.
Results
͸-
cle. The expression of a selection of different bitter taste receptors and taste signalling elements was 
investigated in muscle strip preparations of mouse fundus, antrum, duodenum and colon via RT-PCR. 
No expression was shown for mTAS2R118 (salicin) and mTAS2R138 (phenylthiocarbamide (PTC)), 
while mRNA for mTAS2R108 (DB), mTAS2R135 (DB) and mTAS2R137 (chloroquine) was demonstrated 
throughout the gut with mouse tongue epithelium as positive control (Fig. 1a). Candidate TAS2R-coupled 
G-proteins such as α -gustducin and its corresponding β 3γ 13-subunits, α -transducin, Gα i1, Gα i2, Gα i3, 
were also expressed (Fig.  1b)15–17. The expression of phospholipase C β 2 and TRPM5 confirmed the 
presence of the full canonical bitter taste signalling pathway.
Figure 1. Expression of bitter taste signalling elements in mouse gut muscle and contractility responses 
to DB in the presence and absence of Ca2+-activated K+-channel blockers in mouse fundic smooth 
muscle strips. RT-PCR transcripts coding for (a) mTAS2Rs in mouse gut smooth muscle and tongue 
circumvallate papillae and (b) taste signalling molecules in mouse fundic smooth muscle tissue.  
(c) Representative tracing of the effects of increasing concentrations of DB, in absence or presence of 100 nM 
charybdotoxin (CbTX), on contractility in mouse fundic muscle strips, expressed as gram-force/mm2 (gF/
mm2). (d) Concentration-response curves to DB in the absence (n = 30) or presence of CbTX (n = 71 
mice), iberiotoxin (n = 4), TRAM-34 (n = 4) or apamin (n = 3) in mouse fundic strips. ACh = acetylcholine, 
IP = isoprotenerol, NG = nitroglycerine.
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Bitter taste receptor agonists induce concentration-dependent changes in smooth muscle 
contractility. 
Effects of DB on smooth muscle contractility. In mouse fundic muscle strips, DB induced a 
concentration-dependent tonic contraction, which was maximal at 100 µ M and amounted 12 ± 1% of 
the maximal response to ACh (P < 0.01) (Fig. 1c). At higher concentrations (1 mM), DB relaxed muscle 
strips strongly, up to 83 ± 17% of the maximal relaxation attained by nitroglycerine (NG) (P < 0.001).
To study the involvement of membrane K+ channels in the effect of DB on muscle contractility, 
fundic muscle strips were pretreated with blockers of different types of K+ channels. Blockade of large 
conductance Ca2+-activated K+ (BKCa) channels by iberiotoxin (IbTx, 100 nM), intermediate conduct-
ance Ca2+-activated K+ (IKCa) channels by TRAM-34 (1 µ M) and small conductance Ca2+-activated K+ 
(SKCa) channels by apamin (500 nM) did not affect the contractile response to DB (Fig. 1d). In contrast, 
pretreatment with the promiscuous K+ channel blocker charybdotoxin (CbTX, 100 nM) resulted, sur-
prisingly, in an increased tonic contraction in response to DB (28 ± 2% of response to ACh) (P < 0.001), 
without affecting the relaxation at higher concentrations (Fig.  1c,d). Spikes of phasic contractions in 
fundic muscle strips (Fig. 1c) are a characteristic of CbTX-treatment and do not involve DB treatment.
In the antrum (Fig. 2a) and the colon (Fig. 2b), a similar contractile pattern was observed with DB as 
in the fundus. In the antrum, DB reached a maximal increase in phasic activity, characteristic for antral 
smooth muscle, of 37 ± 7% (P < 0.001) and a maximal tonic contraction of 19 ± 3% (P < 0.001) in the 
colon, both at 50 µ M. Pretreatment with CbTX resulted in a 2-fold and 1.4-fold increase in contractility 
in the antrum and colon respectively. At higher concentrations, DB inhibited the phasic activity in the 
antrum (P < 0.01) and the tonic contraction in the colon.
Figure 2. Specific contractility responses of various bitter taste receptor agonists in smooth muscle 
strips from different regions of the mouse gut. Representative tracing of the effects of increasing 
concentrations of DB, in the absence or presence of 100 nM CbTX, on contractility in mouse antral (a) and 
colonic (b) muscle strips. Cumulative concentration-dependent contractility changes induced by the bitter 
agonists DB, chloroquine, PTC and salicin, in the presence of 100 nM CbTX in mouse antral (c) and colonic 
(d) muscle strips. (N = 3–21 strips, n = 3–12 mice).
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Effects of other bitter tastants on smooth muscle contractility. Chloroquine induced a significant increase 
(34 ± 3%, P < 0.001) in phasic activity of the antrum, followed by an inhibition at higher concentrations 
(P < 0.001) (Fig. 2c). No significant tonic contractions were observed in fundus or colon, but chloro-
quine relaxed (90% relative to NG, P < 0.001) fundic muscle at 500 µ M (P < 0.001) (Fig. S1 and 2d). 
Phenylthiocarbamide did not induce a contraction in any of the tissues tested but relaxed fundic muscle 
strips, up to 51 ± 10% at 5 mM (P < 0.05 Supplementary Fig. S1) and completely inhibited phasic activity 
in the antrum (Fig. 2c, P < 0.001). PTC had no effect in the colon (Fig. 2d). Salicin did not influence 
contractility in any of the tissues tested (Fig. S1, 2c,d).
͸-
ical taste signalling pathway. The DB-induced contraction was further characterized in fundic 
muscle strips and was shown to be muscle-specific, since blockade of neurotransmission with tetrodo-
toxin (3 µ M) did not influence the contraction (Table 1).
Involvement of the taste-signalling cascade was investigated with different blockers of the taste 
signalling pathway. Blockade of TAS2Rs with a TAS2R antagonist (probenecid, 1 mM; P < 0.05 vs 
vehicle-treated muscle strips) (Fig. 3a), the β γ -subunit of G-proteins (gallein, 75 µ M; P < 0.001) (Fig. 3b), 
Blocker (Concentration) Target of blocker
Effect of 
blocker (% 
ACh)
Change in maximal 
contraction in 
absence vs presence 
of blocker
Tetrodotoxin (3 µ M) Na+v-Channels
0 ± 0%, 
P > 0.05
32 ± 6% vs 26 ± 3%, 
P > 0.05 (n = 4)
Indomethacin (10 µ M) Prostaglandin synthesis − 3 ± 0%, P > 0.05
31 ± 5% vs 31 ± 8%, 
P > 0.05 (n = 5)
Nifedipine (1 µ M) L-type Ca2+-channels − 6 ± 3%, P > 0.05
24 ± 7% vs − 3 ± 1%, 
P < 0.01 (n = 3)
Niflumic Acid (20 µ M) Cl−Ca2+-channels
− 12 ± 2%, 
P < 0.01
50 ± 7% vs 24 ± 5%, 
P < 0.01 (n = 5)
Probenecid (1 mM) TAS2R − 5 ± 1%, P > 0.05
33 ± 6% vs 23 ± 4%, 
P < 0.05 (n = 7)
Gallein (75 µ M) β γ -subunit of G-protein 4 ± 2%, P > 0.05
32 ± 5% vs 14 ± 2%, 
P < 0.001 (n = 6)
U-73122 (5 µ M) PLCβ − 6 ± 3%, P > 0.05
23 ± 8% vs 9 ± 2%, 
P < 0.05 (n = 6)
ODQ (10 µ M) cGMP 2 ± 4%, P > 0.05
31 ± 4% vs 31 ± 8%, 
P > 0.05 (n = 2)
SQ-22536 (100 µ M) cAMP − 6 ± 1%, P > 0.05
29 ± 9% vs 33 ± 5%, 
P > 0.05 (n = 5)
KT-5720 (1 µ M) PKA − 2 ± 1%, P > 0.05
39 ± 6% vs 29 ± 6%, 
P > 0.05 (n = 5)
Thapsigargin (10 µ M) SERCA-pump 34 ± 1%, P < 0.01
13 ± 5% vs − 18 ± 9%, 
P < 0.001 (n = 5)
2-APB (50 µ M) IP3-receptor
− 17 ± 2%, 
P < 0.05
34 ± 5% vs 4 ± 2%, 
P < 0.01 (n = 4)
Ryanodine (10 µ M) Ryanodine receptor 4 ± 2%, P > 0.05
39 ± 9% vs 21 ± 6%, 
P > 0.05 (n = 4)
Calphostin C (1 µ M) All PKC − 3 ± 4%, P > 0.05
49 ± 1% vs 4 ± 1%, 
P < 0.001 (n = 3)
GF109203X (3 µ M) Ca2+-dependent PKC − 5 ± 1%, P > 0.05
35 ± 6% vs 14 ± 4%, 
P < 0.05 (n = 4)
Y-27632 (10 µ M) ROCK − 15 ± 2%, P < 0.01
41 ± 4% vs 0 ± 0%, 
P < 0.01 (n = 3)
PD-98059 (10 µ M) MEK − 6 ± 2%, P > 0.05
23 ± 7% vs 12 ± 1%, 
P < 0.05 (n = 5)
SB-203580 (10 µ M) p38MAPK − 8 ± 1%, P > 0.05
27 ± 10% vs 32 ± 4%, 
P > 0.05 (n = 4)
Table 1.  Maximal contractions in response to DB (100 µM) in the presence of CbTX in mouse smooth 
muscle strips. The effects of different pharmacological blockers on basal muscle tension are represented as 
%ACh and are compared to the baseline tension using a paired student’s t-test. The influence of blockers on 
DB-induced contractions is compared between vehicle and blocker-treated strips using repeated measures 
ANOVA.
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PLCβ (U-73122, 5 µ M; P < 0.05) (Fig. 3c), the IP3-receptor (2-APB, 50 µ M; P < 0.01) (Fig. 3d) or endo-
plasmic reticulum-depletion (thapsigargin, 10 µ M; P < 0.001) (Table 1) all inhibited the contractions at 
lower concentrations, without influencing the relaxation at higher concentrations. Ryanodine (10 µ M) 
on the other hand did not influence contractility (Table  1). In addition, contractions in strips from 
α -gustducin−/− mice (α -gust−/−) were significantly lower compared to WT mice (P < 0.001) further 
confirming the involvement of taste signalling in the DB-induced contractions (Fig. 3e).
Ca2+-free buffer or pre-treatment of the strips with the L-type Ca2+-channel blocker nifedipine abol-
ished (P < 0.01) contractions in response to DB indicating that influx of extracellular Ca2+ is impor-
tant. TRPM5 seems not to be involved, since contractions were not different between muscle strips 
Figure 3. Effects of pharmacological blockers on DB-induced contractile responses in mouse fundic 
muscle strips and comparison of the responses to DB in fundic muscle strips of WT and α-gust−/− or 
TRPM5−/− mice. Effect of pharmacological blockers on contractility changes induced by DB in mouse 
fundic smooth muscle strips. CbTX-treated strips were pre-incubated with (a) probenecid (n = 7, P < 0.05), 
(b) gallein (n = 6, P < 0.001), (c) U-73122 (n = 6, P < 0.05) or (d) 2-APB (n = 4, P < 0.01) before addition 
of DB at increasing concentrations. Comparison of DB-induced contractions in WT (N = 15–26 strips, 
n = 5–21 mice) and (e) α -gust−/− (N = 16 strips, n = 9 mice, P < 0.05) or (f) TRPM5−/− (N = 12 strips, n = 3 
mice, P > 0.05) mice in the presence of CbTX.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:15985 | DOi: 10.1038/srep15985
from WT mice and TRPM5−/− mice (Fig. 3f). The Ca2+-influx appears to be dependent on activation 
of Ca2+-activated Cl−-channels, as pre-treatment with niflumic acid (20 µ M; P < 0.01) also inhibited 
DB-induced contractions (Table 1).
Further downstream, involvement of Ca2+-dependent protein kinase C subtypes and ERK-signalling 
was shown via blockade of PKCCa with GF109203X (3 µ M; P < 0.05) and MEK (PD98059, 10 µ M; 
P < 0.05), both inhibiting contractions in response to DB. The Rho-associated protein kinase (ROCK) 
blocker Y-27632 (10 µ M; P < 0.01) also abolished DB-induced contractions (Table 1).
Relaxations in response to higher concentrations of bitter tastants do not involve the canon-
ical taste pathway, but are PKC-dependent. None of the previously tested blockers influenced the 
relaxations at higher concentrations. Neither did inhibition of cAMP/cGMP signalling with SQ-22536 
(cAMP, 100 µ M) or ODQ (cGMP, 10 µ M). In contrast, the general PKC-inhibitor calphostine C (1 µ M; 
P < 0.001) inhibited both DB-induced contractions and relaxations.
Bitter taste receptor agonists inhibit gastric emptying in mice. Intra-gastric administration of 
DB and PTC significantly inhibited (P < 0.001) gastric emptying rate in mice as shown by an increase in 
gastric half-excretion time (T1/2) (DB: 38 ± 9%; PTC: 62 ± 8%) and lag time (Tlag) (DB: 25 ± 4%; PTC: 
44 ± 7%) (Fig. 4). Pretreatment of mice with probenecid (i.p., 50 mg/kg) inhibited the delay in gastric 
emptying induced by DB (treatment x blocker: T1/2: P < 0.05, Tlag: P < 0.06), but not by PTC (Fig. 4).
Bitter taste receptors and associated G-proteins are expressed in human gastric smooth 
  ȋ
ȌǤ In cultured hGSMCs mRNA expression for human bitter taste receptors 
hTAS2R3 (chloroquine), hTAS2R4 (DB), hTAS2R10 (DB) and their associated G-protein subunits 
(α -gustducin and α -transducin), but not hTAS2R38 (PTC) was demonstrated. Human bronchial tissue 
served as positive control (Fig. 5a). Protein expression of α -gustducin and α -transducin was confirmed 
by immunofluorescence (Fig. 5b).
Bitter taste receptor agonists induce functional responses in human gastric smooth muscle 
cells. Both DB (Fig. 5d, P < 0.001) and chloroquine (Fig. 5e, P < 0.05) induced a concentration-dependent 
Figure 4. Effect of the bitter agonists DB or PTC on gastric emptying in mice in the absence or presence 
of the TAS2R antagonist probenecid. Effect of intra-gastric administration of bitter agonists on gastric half-
excretion time (T1/2, a,c) and lag time (Tlag, b,d). Mice (n = 12) were pretreated with vehicle or probenecid 
(i.p., 50 mg/kg), 15 min before oral gavage of DB (a,b) or PTC (c,d). Two-way ANOVA; *P < 0.05, 
***P < 0.001 bitter vs water; #P < 0.05 probenecid vs vehicle.
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Figure 5. Expression of bitter taste signalling elements in human gastric smooth muscle cells and 
functional responses to bitter agonists in these cells. (a) RT-PCR transcripts coding for hTAS2Rs, 
α -gustducin and α -transducin in hGSMCs and human lung tissue. (b) Immunofluorescent stainings of 
hGSMCs for α -gustducin and α -transducin (scale bar = 50 µ m). Negative controls include cells incubated 
with rabbit serum (α -gustducin) or with the specific antigen peptide (α -transducin). Nuclei are stained 
with DAPI. (c) Mean concentration-response curve of [Ca2+]i-rises in response to increasing concentrations 
of DB (n = 8 spots, P < 0.001) and chloroquine (n = 15 spots, P < 0.05) in hGSMCs. (d,e) Representative 
tracing of [Ca2+]i-rises in response to increasing concentrations of DB and chloroquine in a hGSMC.  
(f) Ratio (n = 4) of pErk over Erk, normalized to vinculin, in hGSMC in response to Hepes-buffer or 5 mM 
DB. *P < 0.05 vs Hepes buffer. Inlay: Representative western blot of Erk1/2 phosphorylation after stimulation.
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rise in [Ca2+]i in hGSMCs loaded with the Ca2+-indicator Fluo-4 AM with chloroquine being more 
potent than DB (Fig. 5c).
Activation of the PKC-ERK signalling pathway was demonstrated by western blotting. Stimulation 
of hGSMC with 5 mM DB resulted in an increased phosphorylation of both Erk1 (P < 0.05) and Erk2 
(P = 0.05) (Fig. 5f).
DB inhibits gastric accommodation in healthy volunteers. All volunteers (n = 12) completed the 
study without reporting adverse effects. Baseline intra-gastric pressure (IGP) prior to nutrient drink infu-
sion was not different between placebo and DB. The course of the drop in IGP during nutrient infusion 
differed significantly (treatment: P = 0.01; treatment x time: P = 0.09) between placebo and DB treatment 
(Fig. 6a). IGP at nadir (placebo: − 4.575 vs DB: − 3.104 mmHg) tended (P = 0.06) to be more elevated 
during the DB condition but especially the return from the drop in IGP at nadir was faster after DB.
DB increases satiation scores during liquid meal intake in healthy volunteers. After DB 
administration subjects (n = 13) felt satiated earlier (64 ± 6 min) compared with placebo treatment 
(74 ± 8 min; P = 0.01). Under vehicle conditions subjects ingested 998 ± 133 ml, while after DB treat-
ment this was decreased to 869 ± 96 ml (P = 0.03). None of the other symptom ratings differed between 
DB and placebo (details not shown).
Discussion
This study provided for the first time evidence that functional bitter taste receptors are present on smooth 
muscle cells of the human and mouse gut. Bitter tastants induced contractions in vitro, while intra-gastric 
administration of DB resulted in a TAS2R mediated delay in gastric emptying in mice. In humans, DB 
impaired gastric accommodation in response to intra-gastric nutrient infusion and decreased both time 
to reach full satiation and ingested nutrient volume in a nutrient drinking test. The presence of bitter 
taste receptors on both endocrine and smooth muscle cells in the gut suggests that bitter tastants might 
be used as novel stimuli to alter gastrointestinal motility and hence hunger signalling in man.
The contractile pattern induced by bitter tastants was region specific and agonist selective. DB 
induced a contraction in all tissues tested, followed by a relaxation at higher concentrations in fundus 
and antrum. Chloroquine followed largely the same pattern in the antrum, but was less potent in evok-
ing contractions in fundus and colon. PTC only relaxed gut smooth muscle, while salicin had no effect 
on contractility. The discrepancy between these agonists might be a consequence of a differential bitter 
taste receptor expression in mouse gut smooth muscle. Both substances that to some extent cause con-
tractions have a potential receptor present, but their ability to induce a response might differ depending 
on the sensitivity and number of TAS2Rs that are expressed. Alternatively, different TAS2Rs might elicit 
differential responses upon activation, explaining distinct responses for different bitter agonists. It needs 
to be emphasized that bitter compounds activate various TAS2Rs in different concentration ranges18. For 
instance in humans, DB can interact with 8 different TAS2Rs, chloroquine with 4 TAS2Rs of which two 
in common with DB and PTC does only interact with one receptor. In humans 80% of the 25 TAS2R 
subtypes have been de-orphaned, in mice only 6% of the 33 TAS2R subtypes19. The expression of a 
selection of mTAS2Rs was examined, based on homology to hTAS2Rs activated by the compounds used 
in the present study20.
Figure 6. (a) Intra-gastric pressure in healthy volunteers (n = 12) during intra-gastric nutrient infusion after 
pretreatment with 1 µ mol/kg DB or placebo. (*P < 0.05; **P < 0.01). (b) Overview of the proposed pathway 
for the contraction induced by DB in mouse fundic smooth muscle strips.
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Identifying actual TAS2Rs involved in the effects of bitter tastants on contractility is hampered by 
a lack of molecular tools. Reliable antibodies for TAS2Rs are unavailable and antagonists are scarce. 
TAS2R expression was confirmed by RT-PCR and their function studied using probenecid, the only 
commercially available molecule described to block a subset of TAS2Rs (namely hTAS2R16, − 38 and 
− 43 but not hTAS2R31)21. Probenecid reduced but did not abolish the DB-induced contractions in the 
mouse fundus suggesting that probenecid does not block all DB-activated TAS2Rs or acts with a different 
potency.
Experiments with muscle strips from α -gustducin−/− mice indicate that the taste receptor-associated 
G-protein is involved in the observed effects of bitter tastants on gut contractility. However, since the 
contractions are not fully abolished, other G-proteins are probably in play as well. Indeed, TAS2Rs have 
been shown to couple to several G-proteins, including transducin and the inhibitory G-protein-subunits 
Gα i15–17, all expressed in gut smooth muscle. The taste receptor-associated cation channel TRPM5 
seems, despite its expression in gut smooth muscle, not to be involved in the effects of bitter tastants on 
contractility.
The contraction induced by bitter tastants involves [Ca2+]i increases and Ca2+-sensitization (summa-
rized in Fig. 6b). The increase in [Ca2+]i is mediated by the activation of the canonical taste signalling 
pathway and consequently depolarization of the cell, leading to further Ca2+-influx from the extracellular 
space. Rises in [Ca2+]i in response to bitter tastants have been described in airway smooth muscle, but are 
being claimed to be part of the relaxation mechanism14 on the one hand, or have been considered too low 
to induce a contraction on the other hand22. A recent paper however described Ca2+ mobilization in the 
pulmonary artery in response to various bitter tastants, including DB, and a TAS2R-mediated vasocon-
striction23. We are the first to describe a small contraction in response to bitter tastant-induced Ca2+-rises 
in mouse gut smooth muscle, enhanced by incubation with a promiscuous K+-channel blocker, cha-
rybdotoxin. This suggests that a K+-efflux, causing hyperpolarization, is being induced by bitter taste 
receptor agonists, inhibiting the contraction, possibly by inhibiting L-type Ca2+-channel activation14. The 
Ca2+-sensitizing effect of bitter tastants is mediated via activation of ROCK, known to lead to inhibition 
of myosin light chain phosphatase24.
Bitter tastants induced a relaxation or inhibition of contractile activity at higher concentrations in 
several regions of the gastrointestinal tract. The mechanism behind the relaxation induced by DB in 
the mouse fundus could not be fully elucidated, but appears to be TAS2R-independent. Involvement 
of BK Ca2+-activated K+-channels14 or a direct effect of the β γ -subunits of the G-protein on L-type 
Ca2+-channels, as described in airway smooth muscle22, could not be confirmed. However, a general 
PKC-inhibitor abolished the relaxations, possibly due to a direct attenuating effect of PKC on L-type 
Ca2+-channels, as reported for the inhibitory effects of bile acids on gut smooth muscle25.
Bitter tastants also induced functional effects in vivo. Intra-gastric administration of DB or PTC delayed 
gastric emptying in mice. Moreover, the effect of DB but not of PTC could be blocked by probenecid. 
This confirms that the effect of DB is TAS2R mediated, while that of PTC is not and is in agreement 
with the finding that mice are insensitive to the bitter taste of PTC26 and is further substantiated by 
the absence of mRNA expression for mTAS2R138 in the mouse gut. Some bitter agonists (chloroquine, 
salicin) are absorbed via the lumen and can gain access to the smooth muscle via the bloodstream27,28. 
Although benzoate is readily absorbed it is unclear whether this is also the case for denatonium benzo-
ate29. Therefore, it needs to be emphasized that in vivo other modes of action for bitter agonists besides 
effects on smooth muscle cells are probably in play as well. For instance, DB receptors are expressed in 
the rat brain11 and also the release of gut peptides will play a part in the overall in vivo effect of bitter 
administration on gastric emptying4. A delay in gastric emptying correlating with a decrease in food 
intake in response to bitter tastants has previously been reported, and was shown to be independent of 
CCK or GLP-1 release10,30.
A primary cell culture of human gastric smooth muscle cells was used to determine whether the 
observed effects of bitter tastants in mouse smooth muscle strips were also representative for human 
smooth muscle. Bitter taste receptors, homologous to the ones identified in mouse tissue were found to 
be expressed, as well as α -gustducin and α -transducin. Stimulation of human gastric smooth muscle 
cells with bitter tastants evoked [Ca2+]i rises and phosphorylation of ERK, and thus suggest the presence 
of a mechanism analogous to that described in mouse tissue.
Bitter agonists also induced functional effects in healthy volunteers, since intra-gastric administration 
of DB inhibited the drop in fundic tone in response to nutrient infusion. The functional relevance of 
this response was confirmed during a satiety drinking test, where intra-gastric administration of DB 
was associated with decreased nutrient volume tolerance and earlier satiation without inducing adverse 
symptoms. It still remains to be determined whether the effects described in our pre-clinical models are 
responsible for the observations in humans.
The actual physiological meaning of the dose-dependent changes in contractility in response to bitter 
tastants is not fully clear. Impaired accommodation, measured with the barostat or IGP monitoring, is 
associated with increased satiety and unexplained weight loss in functional dyspepsia31,32. Together with 
a possible inhibition of gastric emptying this may represent a system of highly orchestrated interactions 
that together with the aversive reactions elicited by bitter in the lingual system prevent toxic bitter com-
pounds from being ingested and absorbed into the circulation. In the colon, an increased contractility, 
in combination with increased ionic secretions33 might be effective to expel pathogenic bacteria from 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:15985 | DOi: 10.1038/srep15985
the body. Interaction of bacterial quorum sensing molecules with TAS2Rs has already been shown in 
the airways34.
The current observations indicate potential therapeutic applications for bitter tastants in different dis-
orders. The effect of bitter tastants on gastric accommodation or gastric emptying and hence on satiation 
or satiety might encompass a therapeutic potential in the treatment of obesity. The observed effects on 
contractility in the lower gut suggest possibilities in the treatment of ileus or constipation with bitter 
agonists. The regional specificity of a selective bitter agonist might make it possible to target specific 
regions. However, bitter tastants affect other tissues than mere the smooth muscle, such as the mucosal 
endocrine cells to affect hormone release10, and our observations in vivo are probably a summation of 
these effects. Long-term studies with bitter agonists in animals of disease might shed light on the thera-
peutic potential of TAS2Rs in the gut.
Materials and Methods
Animals. Wild type C57BL/6 (Janvier), α -gust−/− (kindly provided by R. Margolskee, Monell Chemical 
Senses center) and TRPM5−/− (kindly provided by K. Talavera, KU Leuven) mice were kept in the ani-
mal facility in 14–10 light-dark cycle with ad libitum access to chow and water. All experiments were 
approved by and conducted in accordance to the regulations of the ethical committee on animal exper-
iments of the University of Leuven.
  ȋȌ Ǥ Total RNA was extracted from gut smooth muscle tissue and 
human gastric smooth muscle cells/lung tissue using the RNeasy fibrous tissue mini kit or RNeasy mini 
kit (Qiagen), respectively, and treated with the Turbo DNA-free kit (Ambion, Life technologies) to exclude 
genomic DNA contamination before reverse transcription using Superscript II Reverse Transcriptase 
(Invitrogen, Life technologies). 5 different samples per tissue were analyzed in triplicate, originating from 
5 different mice. The RT- PCR reaction was performed as described previously35 and PCR-products were 
analyzed with agarose gel electrophoresis. The primers used are summarized in Supplementary Table S1. 
Amplicons for the TAS2Rs, α -gustducin and α -transducin in mouse fundic smooth muscle and hGSMC 
were extracted from the agarose gel with the Qiaquick gel extraction kit (Qiagen) and sequenced (LGC 
genomics) to confirm primer specificity. Amplicons of TAS2Rs that were not expressed in the target 
tissues were sequenced from the positive controls, mouse tongue and human lung.
In vitro contractility studies in smooth muscle strips. Mucosal-free smooth muscle strips from 
fundus of WT, α -gust−/− and TRPM5−/− and antrum and colon of WT were suspended along their 
circular axis in a Krebs-filled tissue bath. Tension was measured isometrically in response to increasing 
concentrations (10 µ M–10 mM) of the bitter agonists DB, chloroquine, salicin or PTC, in the presence 
and absence of different pharmacological blockers (described in supplementary materials) added 30 min 
before bitter stimulation36.
ͷ͹C Octanoic acid breath test for gastric emptying. Gastric emptying was measured as previously 
described35. Mice (n = 12) were gavaged with either DB (60 µ mol/kg) or PTC (30 µ mol/kg)10 or water, 
as control, 30 minutes prior to start of the measurement. Probenecid (50 mg/kg) or vehicle was injected 
intraperitoneally, 15 min before gavage. Control experiments were run during the first 4 weeks until 
stable gastric emptying times were obtained. Mice were then assigned, using a cross-over design, to the 
following treatments: vehicle+ water, vehicle+ bitter, probenecid+ water and probenecid+ bitter. Between 
each treatment a wash-out period of one week was introduced.
ȋ
ȌǤ hGSMCs 
were purchased from Innoprot and cultured according to the manufacturer’s guidelines. The cells were 
fixated and stained overnight at 4 °C with rabbit anti-α -gustducin (1:200, #79760, Abcam) or rabbit 
anti-α -transducin (1:500, SC-390, Santa Cruz Biotechnology). Negative controls included the addition 
of normal rabbit serum (1:200) instead of the primary antibody (α -gustducin) or blocking the primary 
antibody (1:500) with a 5x excess of its specific blocking peptide (α -transducin, SC-390 P, Santa Cruz), 
according to the manufacturer’s guidelines. Cells were stained with Alexa Fluor 594 donkey anti-rabbit 
IgG (1:750, Invitrogen, Life technologies) as secondary antibody and DAPI (1:1000, Invitrogen, Life 
Technologies) for 2 hours.
Western Blotting. Total protein from hGSMCs was separated using SDS-PAGE and transferred 
on a PVDF membrane. Membranes were incubated overnight at 4 °C with primary antibodies: rab-
bit anti-phospho-p44/42 MAPK (1:1000, #9101, Cell signalling) and rabbit anti-p44/42 MAPK (1:1000, 
#9101, Cell signalling) or mouse anti-vinculin (1:10000, Sigma-Aldrich) as a protein-loading control. 
Secondary antibodies used were peroxidase conjugated goat anti-rabbit IgG or goat anti-mouse IgG 
(1:5000, Sigma-Aldrich) (1h, RT). Bands were quantified by relative densitometry and normalized to 
vinculin, using ImageQuant TL 8.1 (GE Healthcare).
Calcium imaging. hGSMCs, loaded with 10 µ M Fluo-4 AM, were stimulated via a local perfusion sys-
tem (1 ml/min) with increasing concentrations of DB or chloroquine for 60 sec. Changes in [Ca2+]i were 
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reflected as change in Fluo-4 AM fluorescence intensity and recorded at 525/50 nm using an inverted 
Zeiss Axiovert 200M microscope (Carl Zeiss), with TILL Poly V light source (TILL Photonics) and a 
cooled CCD camera (PCO Sensicam QE). Regions of interest were drawn and average fluorescence sig-
nals were normalized to baseline, all using Igor Pro (Wavemetrics).
Gastric accommodation and satiation drinking test in humans. Detailed protocols of these 
experiments can be found in supplementary materials. In short, in a first protocol, healthy volunteers 
(n = 12, 5 males, mean age: 30.6 ± 2.7; mean BMI: 23.8 ± 1.2) underwent two intra-gastric pressure 
(IGP) studies, at least one week apart, with administration of saline or DB in a single-blind fashion. 
After an overnight fast, a high-resolution solid-state manometer system (Manoscan 360, Sierra Scientific 
Instruments) and nutrient catheter were positioned through the nose in the stomach. Following a stabi-
lization period of at least 15 minutes, either 1 µ mol/kg DB or vehicle was infused through the nutrient 
catheter, followed by a 5 ml water flush. After another 30 minutes, nutrient drink (Nutridrink, Nutricia; 
630 KJ) was infused (60 ml/min) directly in the stomach until maximum satiation. Epigastric sensations 
(fullness, nausea, bloating, belching, epigastric pain and abdominal cramps) were scored every 5 min 
using a 100 mm visual analogue scale.
In a second protocol, volunteers received an intra-gastric administration of saline or DB in an identi-
cal manner as in the first protocol. Thirty minutes after drug administration, subjects were requested to 
maintain intake of the liquid meal (Nutridrink, Nutricia) at a fixed rate until full satiation. All procedures 
were approved by and conducted in accordance to the guidelines of the Ethics Committee of the Leuven 
University Hospital.
Statistical analysis. Results are presented as mean ± SEM. Muscle tension in muscle strips in 
response to bitter agonists (gF/mm2) was calculated as the median tension for each dose (fundus and 
colon) or the difference of the 99.5 and 2 percentile (antrum). The latter is done to reflect changes in the 
phasic activity, characteristic for antral muscle strips. The effects of different doses of bitter agonists on 
muscle tension (% of maximal contraction in response to ACh) were analyzed using one-way ANOVA, 
followed by planned comparisons (STATISTICA 12; Statsoft). Effects of pharmacological agents on basal 
muscle tension (% ACh) were analyzed using a paired student’s t-test. Effects of pharmacological agents 
on concentration-dependent contractions were analyzed with repeated measures ANOVA, comparing 
to representative, non-treated strips from the same animal. Effects of pharmacological agents on max-
imal relaxation were analyzed comparing maximal relaxation in response to treatment to the maximal 
relaxation in response to 10 µ M NG with a paired student’s t-test. Differences in gastric emptying were 
analyzed with two-way ANOVA. Effects of bitter tastants on Ca2+-release and ERK-phosphorylation in 
hGSMCs were analyzed with one-way ANOVA and an unpaired student’s t-test respectively. Differences 
in intra-gastric pressures between placebo and DB treatment in healthy volunteers were determined 
using a repeated measures mixed model analysis (SAS), while effects on maximal satiation time, nutrient 
volume intake and epigastric symptoms were analyzed with a paired student’s t-test. Significance was 
accepted at the 5% level.
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